Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Get Alerts KNSA Hot Sheet
Join SI Premium – FREE
HAMILTON, Bermuda, May 29, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the following investor conferences in June:
- Jefferies 2019 Global Healthcare Conference on Wednesday, June 5th at 10:00 a.m. Eastern Time in New York, NY.
- Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11th at 2:00 p.m. Pacific Time in Rancho Palos Verdes, CA.
- JMP Securities 2019 Life Sciences Conference on Wednesday, June 19th at 10:00 a.m. Eastern Time in New York, NY.
A live webcast of Kiniksa’s presentations will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcasts will be available on Kiniksa’s website for 14 days following the conference.
About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa has a pipeline of product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions. For more information, please visit www.kiniksa.com.
Every Second Counts!™
Kiniksa Investor and Media Contact
Mark Ragosa
(781) 430-8289
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Monster Energy's Max Alran Takes First Place in Downhill Mountain Bike Race at the 2026 WHOOP UCI Mountain Bike World Series Les Gets
- Best Crypto Presale: AlphaPepe at $0.02789 Keeps the $1 Roadmap Trade Alive With Public Trading Still Ahead
- Pump.fun (PUMP) Jumps 17% as Solana Meme Mania Returns, AlphaPepe Still Has Its First Big Pump Ahead
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Goldman Sachs, Jefferies & Co, JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share